Navigation Links
PharmAthene Provides Update on Litigation With SIGA Technologies
Date:1/24/2011

ANNAPOLIS, Md., Jan. 24, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that the trial in the Delaware Court of Chancery, which commenced January 3, 2011, in its breach of contract action against SIGA Technologies concluded this past Friday, January 21, 2011. The Company anticipates that post trial briefs in the case and subsequent oral argument in front of the court will be complete by the end of April 2011.

Eric I. Richman, President and Chief Executive Officer of PharmAthene, commented "I am pleased with how our legal team presented our case and look forward to submitting our post-trial briefs and the court rendering its decision, which we anticipate will occur sometime in mid 2011.  

In December 2006, the Company filed a complaint against Siga in the Delaware Court of Chancery, alleging, among other things, that the Company has the right to license exclusively development and marketing rights for Siga's drug candidate, ST-246, pursuant to a merger agreement between the parties that was terminated in October 2006.  The complaint also alleges that Siga failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement. Siga has counter sued claiming that PharmAthene breached its duty to engage in good faith negotiations for a license to ST-246 during the fall of 2006.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law.  Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").  In particular, there can be no assurance that the Company will prevail in its lawsuit against Siga, or that even if the court rules in the Company's favor, the court will award monetary damages or other remedies adequate to fully compensate the Company for its loses.

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmAthene Presents New Anthrax Data at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
2. PharmAthene to Host Third Quarter 2010 Conference Call and Webcast on Thursday, November 11, 2010
3. PharmAthene Announces Closing of $15 Million Public Offering
4. PharmAthene Appoints Eric I. Richman President and Chief Executive Officer
5. PharmAthene Provides Update on NYSE Amex Listing Compliance Plan
6. PharmAthene Completes Previously Announced Registered Direct Offering
7. PharmAthene Presents New Data for Lyophilized rPA Anthrax Vaccine Showing Enhanced Immunogenicity
8. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
9. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
10. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
11. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... , February 18, 2017 Marapharm ... to purchase a Medical Delivery Service with the specific ... transactions between qualified patients and caregivers. The delivery service ... located in the Coachella Valley, California ... Los Angeles area to the West, population ...
(Date:2/18/2017)... Feb. 17, 2017  Pharmaceutical companies have long used advisory ... in development or already on the market.   ... industry to alter how it manages advisory board meetings. To ... Practices, LLC conducted a new study focused on key aspects ... ...
(Date:2/17/2017)... NEW HAVEN, Conn. , Feb. 17, 2017 /PRNewswire/ ... new class of drugs based on protein degradation, today ... oral androgen receptor (AR) PROTAC during a poster session ... Cancers Symposium (ASCO GU) in Orlando, FL. ... today continue to validate our platform and the potential ...
Breaking Medicine Technology:
(Date:2/20/2017)... Houston, TX (PRWEB) , ... February 20, 2017 ... ... he is now offering a full range of emergency dental care at his ... teeth and gums. When patients experience dental emergencies, they are at risk for ...
(Date:2/20/2017)... ... February 20, 2017 , ... Florida Hospital Pepin Heart Institute ... thrombolysis machine, a state-of-the-art device that breaks up life-threatening blood clots by combining ... Foundation. , “We greatly appreciate this gift from Constellation Brands. We are also ...
(Date:2/19/2017)... RI (PRWEB) , ... February 19, 2017 , ... ... is proven to result in better care, and MEDfx and the Delaware Health ... state of Delaware. , As the nation’s first state-wide health information exchange, DHIN ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken ... Stairlift and other Butler products. Ken was impressed with the safety and reliability ... endorse the product on his show. This endorsement by Ken Matthews can be ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
Breaking Medicine News(10 mins):